ST Pharm, a Seoul, South Korea-based provider of nucleic acid manufacturing and development services, has announced an expansion of oligonucleotide manufacturing capacity.

The company is constructing a new facility at its Banwol site. The expansion is expected to be completed by June 2018. Once the new facility starts to run in October 2018, ST Pharm’s oligonucleotide manufacturing capacity will increase to the 2.1-mol scale. The new facility has the capability to add up to the 3.0-mol scale in the future, according to the company.

Source: ST Pharm